We have been studying subcutaneous white adipose tissue (SC WAT) beiging in response to mirabegron, which is a ?3 adrenergic receptor (?3AR) agonist. ?3ARs are found in adipocytes and smooth muscle, and mirabegron is an FDA approved drug for overactive bladder. Treatment of obese, insulin resistant humans for twelve weeks with mirabegron consistently induced SC WAT beiging and this led to improved oral glucose tolerance and a lower HbA1c. The mechanism for improved glucose homeostasis involved both a small improvement in insulin sensitivity and a significant improvement in ?-cell function (insulin secretion) along with an increase in muscle oxidative type 1 fibers; however, there was no weight loss or induction of brown fat. Since pancreatic ?-cells and muscle do not express the ?3AR, the beneficial effects of mirabegron in these cells likely occurred by an indirect mechanism. The physiological effects of mirabegron are likely mediated in part by the induction of beige adipose, which represents a metabolic sink for glucose and lipids and which may alter adipose remodeling. In addition, the changes in adipose tissue and other organs may result in secondary effects that target other tissues.
Specific Aim 1. To examine the effects of the ?3 agonist mirabegron on glucose metabolism, we will comprehensively analyze glucose tolerance, insulin sensitivity, and ?-cell function in prediabetic subjects in a 4-month, placebo-controlled, randomized trial. We will assess changes in adipose tissue including beiging, inflammation, fibrosis, and insulin-stimulated glucose uptake by adipocytes. We will also fully characterize gene expression in SC WAT by RNA-seq to identify potential mechanisms such as altered adipokine profiles.
Specific Aim 2. We hypothesize that mirabegron causes cells that express the ?3AR to change the levels of secreted factors that affect peripheral cell types such as ?-cells and muscle. We will use biochemical and pharmacological approaches to identify the mechanism by which conditioned medium from mirabegron-treated adipocytes increases PGC1? expression in muscle in vitro. We will utilize unbiased approaches to identify changes in lipids, metabolites, and exosome miRNA composition in the adipocyte conditioned media. We will use these approaches to identify molecules altered in plasma by mirabegron treatment that are responsible for the improvement in ?-cell and muscle function. Clinical relevance: Mirabegron treatment has positive effects on glucose tolerance due to improvements in insulin sensitivity and ?-cell function. This may be exploited to prevent conversion of prediabetes to diabetes or used as a therapeutic in diabetics. This application will also increase our understanding of the mechanism(s) by which mirabegron acts, which may reveal new therapeutic targets
This research grant is designed to determine whether chronic treatment with mirabegron, a ?3 adrenergic receptor agonist approved for treatment of over active bladder, improves metabolic homeostasis in prediabetic, obese, research participants. We will also investigate the underlying mechanisms for improved ?-cell function and insulin sensitivity by mirabegron treatment, which we recently demonstrated. There is a tremendous need for new approaches to fight the obesity and type 2 diabetes epidemic, and this research is thus highly relevant to human health.
